

International Society of Antioxidants in Nutrition and Health

First International Conference
on Avian Influenza in humans :

Latest advances on prevention,
therapies and protective measures

Paris
Anti-Avian Influenza
2006

Institut Pasteur, Paris - France

June 29-30, 2006



COMBIMATRIX



Solvay
Pharma



AB Applied
Biosystems



Taylor & Francis Group



Immunity

Cell
PRESS

Oie



www.isanh.com

First International Conference on
Avian Influenza in Humans

**LATEST ADVANCES ON PREVENTION, THERAPIES
AND
PROTECTIVE MEASURES**

Institut Pasteur, Paris, France,
June 29-30 2006

Abstract Book Index

Session 1: Introduction

General Introduction

Dr Guenael Rodier, WHO Europe, Communicable Disease Surveillance and Response, Copenhagen, Denmark

[Abstract](#)

Economic Impact of the Avian Influenza Propagation

Mr Milan Brahmbhatt, Lead Adviser in the East Asia Region of the World Bank, Washington DC, USA

[Abstract+ Powerpoint Presentation](#)

The need of a global task force for influenza

Pr Albert Osterhaus, National Influenza Centre and Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

[Abstract](#)

Session 2: Focus on H5N1

The Widening Host Range and Changing Pathobiology of Eurasian H5N1 Avian Influenza in Domestic and Wild Birds

Dr David Swayne, Southeast Poultry Research Lab, Agricultural Research Service, Athens, Georgia, USA

[Abstract](#)

Influenza H5N1: diagnosis and disease

Dr Menno D. de Jong, Department of Virology, Oxford University Clinical Research Unit (OUCRU), Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

[Abstract](#)

Risk of H5N1 mutations and mammalian adaptation.

Dr Erich Hoffmann, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, USA

[Abstract + Powerpoint Presentation](#)

Importance of the receptor binding surveillance to detect the jumping of the host range of the highly pathogenic bird influenza virus (H5N1) into humans

Yasuo Suzuki, College of life and health sciences, Chubu University, Aichi, Japan

[Abstract](#)

Role of Mathematical Modelling in Pandemic Preparedness

Dr Simon Cauchemez, Department of Infectious Diseases Epidemiology, Imperial College, London, United Kingdom.

[Abstract + Powerpoint Presentation](#)

Pathogenesis of H5N1 a/vietnam/1203/04 in a mouse infection model

James Long, Battelle medical research & evaluation facility, Columbus, USA

[Abstract](#)

Distinct inhibition patterns of influenza A virus between the two most frequent alleles at the porcine MX1 locus

Mélanie Palm, Faculty of Veterinary Medicine, University of Liège, Belgium.

[Abstract](#)

Clinical and laboratory comparison of human infections with dengue, influenza or avian influenza A (H5N1) viruses in Indonesia

Herman Kosasih, Naval Medical Research Unit #2 (NAMRU-2) Jakarta, Indonesia

[Abstract](#)

Session 3: H5N1 Detection, Treatments and Perspectives

Avian influenza in humans: existing treatments, their limits, and new perspectives

Pr Erik De Clercq, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

[Abstract + Powerpoint Presentation](#)

Increased sensitivity to Oseltamivir of the neuraminidase of recent Influenza A (H5N1) viruses

Marie Anne Rameix-Welti, Unité de Génétique Moléculaire des Virus Respiratoires, Institut Pasteur, Paris, France

[Abstract](#)

Novel antivirals targeting influenza virus-specific membrane rafts

Cornelia Schroeder, Jado Technologies, Dresden, Germany

[Abstract](#)

Multivalent lectins as inhibitors of viral fusion and entry in cells: new antiviral mechanism

Pr Leonid Chernomordik, Section on Membrane Biology, Laboratory of Cellular and Molecular Biophysics, National Institute of Child Health and Human Development, Bethesda, USA

[Abstract + Powerpoint Presentation](#)

In silico docking on grid infrastructures to accelerate structure-based design against Influenza A Neuraminidases

Dr Nicolas Jacq, Laboratoire de Physique Corpusculaire of Clermont-Ferrand, CNRS/IN2P3, University of Clermont Ferrand, Aubière, France.

[Abstract + Powerpoint Presentation](#)

Electrochemical influenza surveillance system

Dr Dominic Suci, CombiMatrix Corporation, Mukilteo, USA.

[Abstract](#)

The use of real-time NASBA for the diagnosis of H5N1 Influenza and other respiratory viruses

Dr Guy Vernet, Director of the Emerging Pathogens R&D Department, Biomérieux, Marcy L'Etoile, France.

[Abstract](#)

An alternative neutralization assay for H5N1 influenza a virus using retroviral pseudotypes

Nigel Temperton, MRC/UCL Centre for Medical Molecular Virology, University College London, London, United Kingdom

[Abstract](#)

Development of a real-time PCR assay for the detection of human influenza a (H5N1) virus and sequence comparison of three avian influenza a (H5N1) detected in Switzerland

Yves Thomas, National Centre of Influenza, University Hospital of Geneva, Geneva, Switzerland

[Abstract](#)

THE NA-STAR[®] influenza neuraminidase inhibitor resistance detection kit: chemiluminescence assay for detection and quantification of influenza neuraminidase activity

Corinne Olesen, Applied Biosystems, Bedford, USA

[Abstract](#)

Detection of avian influenza A/H5 viral isolates with highly sensitive, specific and inclusive real-time RT-PCR assays

Olga Petrauskene, Applied Biosystems, Foster City, USA

[Abstract](#)

Session 4: How to prevent Human and Avian Influenza?

The international response on avian influenza

Dr Christianne Brusckhe, OIE, Paris, France

[Abstract + Powerpoint Presentation](#)

Strategies to prevent avian influenza in humans in a non pandemic frame

Pr Didier Houssin, Interministry Delegate for the Fight against Avian Influenza, French Ministry of Health, Paris, France

Prevention through immunization: latest advances on vaccination

Pr Sylvie Van der Werf, Molecular Genetic of Respiratory Viruses Institut Pasteur, Paris, France

[Abstract](#)

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Dr Suryaprakash Sambhara, Centers for Disease Control and Prevention, Atlanta, USA

[Abstract + Powerpoint Presentation](#)

A new approach for an influenza virus live vaccine by modification of the cleavage site of the haemagglutinin by reverse genetics

Juergen Stech, Institute of Virology, University Hospital Giessen-Marburg, Germany

[Abstract](#)

Development of vaccines against pandemic influenza : Safety, immunogenicity and prospects of an inactivated split-virion H5N1 influenza vaccine

Dr Agnes Hoffenbach, Influenza Franchise Program Leader, Sanofi Pasteur, Marcy l'Etoile, France

[Abstract](#)

Respiratory protection against avian influenza

Pierre Jean Messier, Triosyn Corporation , USA

[Abstract](#)

Antiviral effect of catechins in green tea on influenza virus

Pr Baik-Lin Seong, Yonsei University, Seoul, South Korea

[Abstract](#)

Pandemic Influenza: a potential role for statins in treatment and prophylaxis

Pr David Fedson, Former Professor of Medicine, University of Virginia School of Medicine, Sergy Haut, France

[Abstract](#)

Subtype-diverse inactivation of influenza A viruses including H5N1 with an extract of *Trifolium* species and pomegranate juice

Girish Kotwal, Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town School of Medicine, Cape Town, South Africa

[Abstract](#)

Session 5: Disaster Management Response

Medical and non medical challenges in avian influenza pandemic

Pr Jean Philippe Derenne, Department of Pneumology, La Pitié Salpêtrière Hospital, Paris, France

[Abstract](#)

Ethical Challenges in Pandemic Planning

Dr Ross E.G. Upshur, Joint Centre for Bioethics Flu Pandemic Working Group Member, University of Toronto, Toronto, Canada

[Abstract + Powerpoint Presentation](#)

POSTER SECTION

Anti-influenza Virus Activity of 3-O-alkyl-(+)-catechin and 3-O-alkyl(-)-epigallocatechin Derivatives

Jae-Min Song, Department of Biotechnology, College of Engineering, Yonsei University, Seoul, Korea

[Abstract](#)

Altered expression of the porcine orthomyxovirus resistance gene (mx1) by naturally-occurring polymorphisms in the promoter region

A. Decreux, Faculty of Veterinary Medicine, University of Liège, Belgium

[Abstract](#)

Molecular epidemiology of H5N1 strains in South-Western Nigeria

Mariette F. Ducatez, Institute of Immunology, National Public Health Laboratory, Luxembourg

[Abstract](#)

Multisite monitoring of human influenza surveillance development networks in India

Dr Harpreet Kaur, Indian Council of Medical Research, New Delhi, India

[Abstract](#)

Characteristic avian influenza cases in Indonesia July 2005 - June 2006

Vivi Setiawaty, National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Indonesia

[Abstract](#)

Are The Influenza Antigen Tests Sensitive To H5N1 ?

Yilmaz, N., The Ministry of Health, Refik Saydam Hygiene Center, National Influenza Reference Center, Ankara, Turkey

[Abstract](#)

Avian Influenza Outbreak in Turkey

Yilmaz, N., The Ministry of Health, Refik Saydam Hygiene Center, National Influenza Reference Center, Ankara, Turkey

[Abstract](#)

The study of genetic variety of influenza A viruses of high pathogenic H5N1 subtype that were isolated during the epizootic in period from 2005 to 2006 in Russian Federetion

A.M.Shestopalov, National Scientific Center of Virology and Biotechnology "Vector" of Rospotrebnadzor, Novosibirsk, Russia

[Abstract](#)

The hygenic cleansing aid

Mr. Michael R. Hennigan, Lamar University, Beaumont, TX USA

[Abstract](#)

A successful treatment of the pandemic influenza of 1918 and possible mechanisms of its efficacy

D. M. Neustadter, Israel

[Abstract](#)

Influenza antivirals and pandemic stockpiles: Approaches to risk-sharing and financing

Dr Buddhima Lokuge, The Australian National University, Canberran, Australia

[Abstract](#)

Avian Influenza and WTO Sanitary Phytosanitary Rules: The Economics of Transboundary Disease Control in Developing Countries

Dr Buddhima Lokuge, The Australian National University, Canberran, Australia

[Abstract](#)

Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?

Dr Buddhima Lokuge, The Australian National University, Canberran, Australia

[Abstract](#)

Knowledge and concern of avian influenza among secondary school students

Moataz Abdel-Fattah, Preventive Medicine Departments, Al-Hada Armed Forces hospital, Taif, Saudi Arabia.

[Abstract](#)

The Threat of Avian Flu

Luc Montagnier

[Abstract](#)



Abstract Book Purchase

I would like to purchase the following abstract book (including shipment fees)

<input type="checkbox"/>	June 28-29 : First International Conference on Avian Influenza in Humans : Latest Advances on Prevention, Therapies and Protective Measures	250 €HT
--------------------------	---	---------

TOTAL Amount : **TTC**

Mrs, Ms, Mr First Name :
Last Name :
Company :
Function :
Address:.....
.....
Zip Code :
City:.....
Country :
Phone : Fax :
Email :

Payment :

- **by bank transfer** to National Bank of Paris (BNP),59 Avenue d'Italie 75013 Paris.***
Bank Code :30004
Agency :00895
Account number :00010008521 Key :26
IBAN :FR 76 3000 4008 9500 0100 0852 126 CODE SWIFT : BNPA FR PPP GB
***Fees at your charge

- **by certified cheque** made payable to Takayama with this form

- **by credit card** : AMERICAN EXPRESS – EURO/MASTER/ACCESS – VISA

Name of the cardholder:

Credit Card Number : Expiry Date :

Date :

Signature :

Please return this form **by fax** or mail to :
Paris Anti-Avian Influenza 2006 - TAKAYAMA
15 rue de la Paix - 75002 Paris - France
Phone 00 33 1 55 04 77 55 – Fax : 00 33 1 55 04 77 57
influenza2006@wanadoo.fr - www.isanh.com